Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

Corvus Pharmaceuticals (CRVS)

Corvus Pharmaceuticals Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:CRVS
DateTimeSourceHeadlineSymbolCompany
07/05/202422:19Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:CRVSCorvus Pharmaceuticals Inc
07/05/202422:16Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:CRVSCorvus Pharmaceuticals Inc
07/05/202422:06Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CRVSCorvus Pharmaceuticals Inc
06/05/202421:11Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CRVSCorvus Pharmaceuticals Inc
06/05/202421:01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CRVSCorvus Pharmaceuticals Inc
06/05/202421:01GlobeNewswire Inc.Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2024 Financial ResultsNASDAQ:CRVSCorvus Pharmaceuticals Inc
02/05/202421:02GlobeNewswire Inc.Corvus Pharmaceuticals to Provide Business Update and First Quarter 2024 Financial Results on May 6, 2024NASDAQ:CRVSCorvus Pharmaceuticals Inc
02/05/202413:30GlobeNewswire Inc.Corvus Pharmaceuticals Announces Pricing of $30.6 Million Registered Direct OfferingNASDAQ:CRVSCorvus Pharmaceuticals Inc
09/04/202421:01GlobeNewswire Inc.Corvus Pharmaceuticals Announces Initiation of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic DermatitisNASDAQ:CRVSCorvus Pharmaceuticals Inc
19/03/202420:02GlobeNewswire Inc.Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:CRVSCorvus Pharmaceuticals Inc
19/03/202411:27IH Market NewsUS Index Futures Decline Ahead of Federal Reserve Meeting, Oil Prices RetreatNASDAQ:CRVSCorvus Pharmaceuticals Inc
13/03/202420:02GlobeNewswire Inc.Corvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2023 Financial Results on March 19, 2024NASDAQ:CRVSCorvus Pharmaceuticals Inc
01/03/202422:57Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CRVSCorvus Pharmaceuticals Inc
12/02/202413:30GlobeNewswire Inc.Corvus Pharmaceuticals Presents Soquelitinib Preclinical Data at the Keystone Symposia on Systemic Autoimmune and Autoinflammatory DiseasesNASDAQ:CRVSCorvus Pharmaceuticals Inc
08/02/202421:27Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:CRVSCorvus Pharmaceuticals Inc
08/02/202421:05GlobeNewswire Inc.Corvus Pharmaceuticals Announces Orphan Drug Designation Granted to Soquelitinib for the Treatment of T Cell LymphomaNASDAQ:CRVSCorvus Pharmaceuticals Inc
06/02/202421:05GlobeNewswire Inc.Corvus Pharmaceuticals Appoints Jeffrey Arcara as Chief Business OfficerNASDAQ:CRVSCorvus Pharmaceuticals Inc
23/01/202422:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CRVSCorvus Pharmaceuticals Inc
23/01/202422:00GlobeNewswire Inc.Corvus Pharmaceuticals Announces the Passing of Board Member Edith P. MitchellNASDAQ:CRVSCorvus Pharmaceuticals Inc
09/12/202317:00GlobeNewswire Inc.Corvus Pharmaceuticals Presents New Interim Soquelitinib Data from its Phase 1/1b T Cell Lymphoma TrialNASDAQ:CRVSCorvus Pharmaceuticals Inc
08/12/202321:07Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CRVSCorvus Pharmaceuticals Inc
08/12/202321:03Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CRVSCorvus Pharmaceuticals Inc
07/11/202321:03Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CRVSCorvus Pharmaceuticals Inc
07/11/202321:02Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:CRVSCorvus Pharmaceuticals Inc
07/11/202321:01GlobeNewswire Inc.Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2023 Financial ResultsNASDAQ:CRVSCorvus Pharmaceuticals Inc
02/11/202313:15GlobeNewswire Inc.Corvus Pharmaceuticals to Present New Interim Soquelitinib Data from its Phase 1/1b T Cell Lymphoma Trial at the 65th American Society of Hematology (ASH) Annual Meeting & ExpositionNASDAQ:CRVSCorvus Pharmaceuticals Inc
01/11/202323:31GlobeNewswire Inc.Corvus Pharmaceuticals Announces Publication of Preclinical Data Demonstrating Potential of ITK Inhibition with Soquelitinib as a Novel Approach to T Cell-Mediated Inflammatory and Immune DiseasesNASDAQ:CRVSCorvus Pharmaceuticals Inc
31/10/202320:02GlobeNewswire Inc.Corvus Pharmaceuticals to Provide Business Update and Report Third Quarter Financial Results on November 7, 2023NASDAQ:CRVSCorvus Pharmaceuticals Inc
06/09/202321:05GlobeNewswire Inc.Corvus Pharmaceuticals Confirms Planned Initiation of Soquelitinib (CPI-818) Phase 3 Registrational Clinical Trial in Peripheral T Cell Lymphoma Following Meeting with FDANASDAQ:CRVSCorvus Pharmaceuticals Inc
08/08/202321:02Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:CRVSCorvus Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:CRVS

Your Recent History

Delayed Upgrade Clock